Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ADMA BIOLOGICS, INC. (ADMA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M | $42.2M | $29.3M | $17.0M | $22.8M | $10.7M | $7.2M | $5.9M | $3.1M | $1.1M | $761,042 |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M | −$19.1M | — | −$25.2M | −$6.4M | $4.3M | $2.9M | $2.2M | $1.0M | $449,062 | $553,472 |
| Research & development | $4.8M | $1.8M | $3.3M | $3.6M | $3.6M | $5.9M | $2.3M | $3.9M | $5.6M | $7.7M | $7.0M | $9.5M | $9.3M | $3.5M | $646,756 |
| Operating expenses | $101.3M | $80.6M | $67.3M | $74.6M | $59.5M | $45.8M | $70.8M | $77.3M | $62.1M | $28.0M | $22.7M | $21.9M | $18.1M | $9.0M | $5.2M |
| Operating income | $191.4M | $139.0M | $21.6M | −$39.4M | −$58.4M | −$64.9M | −$41.4M | −$60.3M | −$39.3M | −$17.3M | −$15.5M | −$16.0M | −$15.0M | −$7.9M | −$4.6M |
| EBITDAderived | $199.4M | $146.7M | $29.2M | −$33.0M | −$53.6M | −$61.7M | −$39.0M | −$57.7M | −$37.8M | −$16.9M | −$15.0M | −$15.8M | −$14.8M | −$7.7M | −$4.4M |
| Net income | $146.9M | $197.7M | −$28.2M | −$65.9M | −$71.6M | −$75.7M | −$48.3M | −$65.7M | −$43.8M | −$19.5M | −$18.0M | −$16.8M | −$15.5M | −$7.3M | −$5.9M |
| Basic EPSper diluted share | $0.62 | $0.85 | -$0.13 | -$0.33 | -$0.51 | -$0.88 | -$0.89 | -$1.45 | -$1.91 | -$1.61 | -$1.73 | -$1.81 | -$2.38 | -$1.39 | -$16.72 |
| Diluted EPSper diluted share | $0.60 | $0.81 | -$0.13 | -$0.33 | -$0.51 | -$0.88 | -$0.89 | -$1.45 | -$1.91 | -$1.61 | -$1.73 | -$1.81 | -$2.38 | -$1.39 | -$16.72 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | Grossman Jerrold BDirector | BuyCommon Stock | 6.4K | $7.91 | $50.6K | 520.3K |
| May 12, 2026Form 4 | Grossman Jerrold BDirector | BuyCommon Stock | 12.5K | $8.01 | $100.1K | 513.9K |
| May 11, 2026Form 4 | Grossman Jerrold BDirector | BuyCommon Stock | 12.5K | $8.01 | $100.1K | 501.4K |
| Mar 16, 2026Form 4 · 10b5-1 | Grossman Adam SPresident and CEO | SellCommon Stock | 6.0K | $15.16 | $91.0K | 2.11M |
| Mar 16, 2026Form 4 · 10b5-1 | Grossman Adam SPresident and CEO | SellCommon Stock | 15.0K | $15.16 | $227.4K | 2.12M |